Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Politics Aside
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(548)
•••
Comment by Rumpl3StiltSkinon Nov 06, 2021 8:52am
209 Views
Post# 34095410

RE:RE:RE:Politics Aside

RE:RE:RE:Politics Aside
CancerSlayer wrote:

 

enriquesuave wrote: I'm hoping we can get 3 out the next 6 CR or better. ( even 2 out of 6 would be decent). That would make it 7 out of 12 patients who got optimized treatment in PH2  or 9 out of 14 if we include the 2 from PH1 who also get an optimized treatment.  We would be beating competition at 3 months data and with only one single treatment Vs many many more.  Of course anything better and we start to make the competition look real bad.  All IMo 

 

 

Thanks for keeping track of the optimized treatment numbers...it can be a blur sometimes.  Just hoping the team spells out this data clearly in their next update.  Really liking our simplified two-treatment approach, which most definitely should encourage patient enrollment/retention.  

On the flip-side, the treatment burden & side effects of the other "treatment-intensive" options often promote poor patient retention/compliance.  Their loss just might be our gain imo.



Great points Slayer!

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities